Cytel Chief Data Officer & Head of Europe Dr. Radek Wasiak discusses how Cytel has expanded to utilize health economics and outcomes research (HEOR) and real world evidence (RWE). He notes that the COVID-19 pandemic has led to more interest into and recognition of the value of RWE.
According to Wasiak, “Adding HEOR and RWE capabilities was a natural extension of Cytel’s commitment to using data to glean scientific insights about clinical research. First, we wanted to ensure that we complement our clinical trial expertise by adding real-world data applications for regulatory purposes. Secondly, we wanted to expand our analytical capabilities for methods used to understand the humanistic and economic burden of illness, showing the power of new medical interventions to alleviate these burdens through rigorous comparative effectiveness research.” Read more here.
(Source: Cytel, 5/13/2021)